Project Grant R21AG094020
Award Date 1/1/26
Completion Date 12/31/27
Dollars Obligated $481K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- This $6,368,544 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the role of the SORL1 gene in the pathogenesis and pathophysiology of Alzheimer's disease. The award, with a performance period from September 15, 2025 to May 31, 2030, will be utilized by the lead awardee, The Trustees of Columbia University in the City of New York, to conduct comprehensive research on SORL1 variants and their impact on the retromer trafficking complex,...
- This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
- This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 (Aging Research) provides $1,257,528 to Novoron Bioscience Inc. to develop a platform using human induced pluripotent stem cell (iPSC)-derived neural organoids to screen for compounds that can inhibit the propagation and aggregation of pathological tau protein, a key driver of Alzheimer's disease and other tauopathies. The award aims to establish a robust, multi-faceted screening system that can identify and...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to gain a mechanistic understanding of the role of cellular senescence in the pathogenesis of Alzheimer's disease (AD). The $460,625 grant will fund research at the University of Massachusetts Medical School to dissect the separate P53/P21 and P16 senescence pathways and their functional consequences in AD using human induced pluripotent stem cell-based models. The 2-year project will produce...
- This $6,720,148 federal project grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop short RNA therapeutics that combat TDP-43 proteinopathy, which is a key pathological feature of several devastating neurodegenerative disorders including Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, and chronic traumatic encephalopathy. The project will establish methods to prevent and reverse the aberrant phase transitions of TDP-43, a...
- The Project Grant award of $404,058 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research to identify novel small molecules that stabilize functional, multimeric forms of the TDP43 protein. The goal is to restore TDP43's native RNA binding and splicing regulation functions, which are impaired in frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and other TDP43-related neurodegenerative diseases. The research will leverage high-throughput...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $433,125 will fund a study to investigate the relationship between microglia, neurons, and tau pathology in Alzheimer's disease. The research will utilize a novel model system of microglial co-cultures with hippocampal assembloids derived from patient-derived induced pluripotent stem cell (iPSC) lines with MAPT mutations and healthy controls. The goal is to explore how bidirectional changes...
- This $603,031 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Northwestern University supports a 1-year research study on the clinical, cellular, and pathological features of comorbid Alzheimer's disease and TDP-43 proteinopathies in elderly patients with amnestic dementia. The key objectives are to: 1) identify the shared versus distinct clinical, neuropsychological, and psychiatric characteristics of this condition; 2) determine the cellular...
- The University of Washington was awarded a $100,012 project grant from the National Institute on Aging (CFDA 93.866 Aging Research) on February 26, 2025. The grant supports research to investigate disruptions to nuclear proteostasis machinery as drivers of neurodegeneration in age-related dementias such as Alzheimer's disease and frontotemporal lobar degeneration. The project aims to build on the principal investigator's prior work demonstrating the role of the nuclear ubiquitin proteasome...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,275,512.00 in funding to The Regents of the University of California, San Francisco (UCSF) to conduct research on the impact of progranulin species on TDP-43 proteolysis and pathobiology in neurodegenerative disorders such as Alzheimer's disease, frontotemporal dementia, and limbic-predominant age-associated TDP-43 encephalopathy. The research aims to determine how changes in the...